Allogene Therapeutics, Inc. (ALLO)
ALLO Stock Price Chart
Explore Allogene Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ALLO price movements and trends.
ALLO Company Profile
Discover essential business fundamentals and corporate details for Allogene Therapeutics, Inc. (ALLO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Oct 2018
Employees
226.00
Website
https://www.allogene.comCEO
David D. Chang
Description
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
ALLO Financial Timeline
Browse a chronological timeline of Allogene Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.16, while revenue estimate is $2.22k.
Earnings released on 13 May 2026
EPS came in at -$0.18 surpassing the estimated -$0.19 by +5.26%.
Earnings released on 12 Mar 2026
EPS came in at -$0.17 surpassing the estimated -$0.25 by +32.00%.
Earnings released on 6 Nov 2025
EPS came in at -$0.19 surpassing the estimated -$0.23 by +17.39%.
Earnings released on 13 Aug 2025
EPS came in at -$0.23 surpassing the estimated -$0.28 by +17.86%.
Earnings released on 13 May 2025
EPS came in at -$0.28 matching the estimated -$0.28.
Earnings released on 13 Mar 2025
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $22.00k , beating expectations by +83.33%.
Earnings released on 7 Nov 2024
EPS came in at -$0.27 surpassing the estimated -$0.34 by +20.59%.
Earnings released on 7 Aug 2024
EPS came in at -$0.32 surpassing the estimated -$0.35 by +8.57%.
Earnings released on 13 May 2024
EPS came in at -$0.38 matching the estimated -$0.38, while revenue for the quarter reached $22.00k , beating expectations by +120.00%.
Earnings released on 14 Mar 2024
EPS came in at -$0.43 surpassing the estimated -$0.47 by +8.51%, while revenue for the quarter reached $21.00k , beating expectations by +5.00%.
Earnings released on 2 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.53 by +30.19%, while revenue for the quarter reached $43.00k , beating expectations by +115.00%.
Earnings released on 2 Aug 2023
EPS came in at -$0.53 surpassing the estimated -$0.59 by +10.17%, while revenue for the quarter reached $44.00k , beating expectations by +120.00%.
Earnings released on 3 May 2023
EPS came in at -$0.68 falling short of the estimated -$0.63 by -7.94%, while revenue for the quarter reached $52.00k , beating expectations by +420.00%.
Earnings released on 28 Feb 2023
EPS came in at -$0.66 surpassing the estimated -$0.71 by +7.04%, while revenue for the quarter reached $47.00k , missing expectations by -39.10%.
Earnings released on 2 Nov 2022
EPS came in at -$0.58 surpassing the estimated -$0.62 by +6.45%, while revenue for the quarter reached $49.00k , beating expectations by +583.69%.
Earnings released on 9 Aug 2022
EPS came in at -$0.52 surpassing the estimated -$0.61 by +14.75%, while revenue for the quarter reached $86.00k , beating expectations by +594.39%.
Earnings released on 4 May 2022
EPS came in at -$0.56 surpassing the estimated -$0.59 by +5.08%, while revenue for the quarter reached $61.00k , beating expectations by +632.03%.
Earnings released on 23 Feb 2022
EPS came in at -$0.54 surpassing the estimated -$0.61 by +11.48%, while revenue for the quarter reached $51.00k , missing expectations by -9.09%.
Earnings released on 4 Nov 2021
EPS came in at -$0.57 falling short of the estimated -$0.56 by -1.79%, while revenue for the quarter reached $49.00k , beating expectations by +390.00%.
Earnings released on 4 Aug 2021
EPS came in at -$0.53 surpassing the estimated -$0.55 by +3.64%, while revenue for the quarter reached $44.00k , missing expectations by -80.87%.
ALLO Stock Performance
Access detailed ALLO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
